Foresite Capital Management III, LLC - AIMMUNE THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Foresite Capital Management III, LLC ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2019$12,813,000
-4.9%
611,893
-5.5%
4.89%
+10.7%
Q2 2019$13,476,000
-6.8%
647,2540.0%4.42%
+17.3%
Q1 2019$14,466,000
-14.8%
647,254
-8.8%
3.77%
-32.5%
Q4 2018$16,979,000
-22.3%
709,822
-11.4%
5.58%
+15.6%
Q3 2018$21,858,000
-4.5%
801,240
-5.9%
4.82%
-2.2%
Q2 2018$22,889,000
-23.1%
851,213
-9.0%
4.93%
-24.0%
Q1 2018$29,762,000
+2.9%
935,020
+22.3%
6.49%
-20.1%
Q4 2017$28,926,000
+27.9%
764,824
-16.1%
8.12%
+30.4%
Q3 2017$22,609,000
+20.6%
912,0010.0%6.23%
+1.7%
Q2 2017$18,751,000
-5.4%
912,0010.0%6.12%
-19.5%
Q1 2017$19,818,000
+7.2%
912,001
+0.9%
7.61%
-5.3%
Q4 2016$18,485,000
+31.8%
903,890
-3.3%
8.03%
+22.5%
Q3 2016$14,025,000
+451.5%
935,020
+297.8%
6.56%
+275.6%
Q2 2016$2,543,000
-47.2%
235,020
-33.8%
1.74%
-53.2%
Q1 2016$4,814,000
-26.5%
355,0200.0%3.72%
-35.9%
Q4 2015$6,550,000355,0205.81%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
TLP GROUP LLC 2,904,185$43,563,00046.00%
Foresite Capital Management II, LLC 3,967,900$59,519,00028.42%
Aisling Capital LLC 2,990,000$44,850,0009.24%
Foresite Capital Management III, LLC 935,020$14,025,0006.56%
Vivo Capital, LLC 763,009$11,445,0003.57%
RA Capital Management 1,292,940$19,394,0002.00%
Palo Alto Investors LP 379,727$5,696,0000.33%
EMERALD MUTUAL FUND ADVISERS TRUST 418,214$6,273,0000.32%
EMERALD ADVISERS, LLC 464,364$6,965,0000.31%
Rock Springs Capital Management LP 293,000$4,395,0000.28%
View complete list of AIMMUNE THERAPEUTICS INC shareholders